Genmab A/S (GNMSF) Restructuring Costs (2024 - 2026)

Genmab A's (GNMSF) quarterly Restructuring Costs came in at -$45.0 million in Q1 2026, down 15.38% on a QoQ basis from -$39.0 million in Q3 2024.

Genmab A/S (GNMSF) Restructuring Costs (2024 - 2026) Analysis & Trends

Genmab A (GNMSF) has 2 years of Restructuring Costs data on file, last reported at -$45.0 million in Q1 2026.

Quarterly Restructuring Costs changed N/A year-over-year to -$45.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$120.0 million (changed N/A YoY) and the FY2025 annual result came in at -$185.0 million, down 478.12% from the prior year.
Restructuring Costs fell to -$45.0 million in Q1 2026, from -$39.0 million in the prior quarter.
In the past five years, Restructuring Costs ranged from a high of -$36.0 million in Q2 2024 to a low of -$45.0 million in Q1 2026.

Download Data